For the complete activity, including supporting material, please visit https://www.peervoice.com/ACQ860. Presented by Colin M. Dayan, MA, MBBS, FRCP, PhD; Michael J. Haller, MD; and Olga Kordonouri, MD. Learning Objectives: Explain the clinical rationale and existing evidence for use of immunomodulatory therapies to delay the progression of type 1 diabetes (T1D); Identify practical workflows and protocols that facilitate the potential integration of immunomodulatory infusions into endocrinology practice, including care pathways for T1D; Evaluate patient perspectives and considerations related to the receipt of immunomodulatory infusions for T1D.

For the complete activity, including supporting material, please visit https://www.peervoice.com/PXK860. Presented by Javier Ampuero, MD, PhD and Meena B. Bansal, MD, FAASLD. Learning Objectives: Explain the rationale for prompt identification and active management of individuals with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, based on the increased risk of adverse liver outcomes associated with progression of fibrosis; Evaluate the impact of novel MASH-targeted therapies, such as THR-β agonists, on the underlying pathophysiology and progression of the disease; Identify proactive and systematic approaches that can be practically implemented in gastroenterology practices for the assessment of fibrosis risk in individuals with specific characteristics and comorbid conditions.

For the complete activity, including supporting material, please visit https://www.peervoice.com/TZX860. Presented by Jonathan Barratt, PhD, FRC. Learning Objectives: Describe the relationship between the multi-hit hypothesis and disease trajectory in patients with IgA nephropathy (IgAN); Summarise the role and therapeutic implications of complement pathway dysregulation in IgAN disease progression; Differentiate between emerging therapeutic targets under investigation in patients with IgAN; Interpret data from clinical trials examining emerging therapies, including complement inhibitors, in the context of emerging guidance and approaches to IgAN management.

For the complete activity, including supporting material, please visit https://www.peervoice.com/FAN860. Presented by Austin Kulasekararaj, MD, MRCP, FRCPath; and Bruno Fattizzo, MD Learning Objectives: Discuss the criticality of achieving and sustaining terminal complement inhibition in patients with paroxysmal nocturnal haemoglobinuria (PNH), and the evidence for C5 inhibitor therapy on key efficacy outcomes; Recognise that extravascular haemolysis (EVH) is a potential limitation of terminal complement inhibition with C5 inhibitors and the need to target proximal complement blockade in patients with PNH who are experiencing clinically significant EVH (csEVH); Apply current clinical evidence to develop an optimised treatment strategy for patients with PNH experiencing csEVH while receiving C5 inhibitor therapy; Analyse and interpret the clinical evidence regarding severe breakthrough haemolysis in patients receiving proximal complement inhibition.

For the complete activity, including supporting material, please visit https://www.peervoice.com/CMY860. Presented by Ashkan Shoamanesh, MD, FRCPC; Valeria Caso, MD, PhD; Seemant Chaturvedi, MD; and Jeffrey L. Saver, MD, FAHA, FAAN, FANA. Learning Objectives: Explain the rationale and potential role for use of Factor XIa (FXIa) inhibition in the prevention of ischemic stroke following an acute non-cardioembolic ischemic stroke (NCIS) or high-risk transient ischemic attack (TIA); Evaluate the design and methodology of enrolled populations for key phase 3 trials of FXIa inhibitors for secondary stroke prevention (SSP); Recall the baseline characteristics observed in key phase 3 trials of the use of FXIa inhibition as part of a dual pathway inhibition strategy for SSP.

For the complete activity, including supporting material, please visit https://www.peervoice.com/QDZ860. Presented by David Kavanagh, MBChB, PhD, FRCP; and Kerstin Amann, MD>. Learning Objectives: Identify key histopathological findings from renal biopsy specimens of patients with IgAN, C3G, and IC-MPGN; Describe how complement pathway dysregulation manifests in clinicopathological features of IgAN, C3G, and IC-MPGN; Apply evidence-based diagnostic technologies, including electron microscopy, to support accurate diagnosis in IgAN, C3G, and IC-MPGN; Utilise validated grading systems to assess disease severity and inform clinical decision-making in patients with IgAN, C3G, and IC-MPGN.

For the complete activity, including supporting material, please visit https://www.peervoice.com/GNV860. Presented by Cristina Saura Manich, MD, PhD and Aditya Bardia, MD. Learning Objectives: Evaluate the clinical data for emerging therapeutic strategies for the management of HER2+ metastatic breast cancer in the first-line setting; Discuss key learnings from clinical trials for investigative first-line treatment approaches for HER2+ metastatic breast cancer in context of different patient and disease characteristics.

For the complete activity, including supporting material, please visit https://www.peervoice.com/SDW860. Presented by Yohei Doi, MD, PhD and Sarah Jarvis, MBE, FRCGP. Learning Objectives: Differentiate key clinical and demographic factors, including age, comorbidities, and immune status, that define high-risk COVID-19 patient profiles; Propose strategies to improve early identification of high-risk patients for appropriate COVID-19 treatment; Interpret regional epidemiological data from Europe and Asia-Pacific to contextualise risk profiles for diverse patient populations; Apply clinical criteria and actionable cues to recognise the optimal therapeutic window for initiating COVID-19 treatment in practice; Evaluate the role of overlapping risk factors in intensifying COVID-19 disease progression; Assess the data from real-world studies of the potential impact of established treatments on clinical outcomes, including long COVID.

Visit https://www.peervoice.com/URW860 to view the entire programme with slides. After completing “Ira Goldberg, MD - Mastering the Fundamentals of Care for Chylomicronemia: Following the Patient Care Pathway From Differential Diagnosis to Modern Management”, participants will be able to: Identify patients with persistent chylomicronemia, including familial chylomicronemia syndrome (FCS), based on clinical presentation and recommended diagnostic criteria; Recall the mechanisms of and evidence for novel treatments for management of FCS; and Apply comprehensive, patient-centered approaches to the management of persistent chylomicronemia, including FCS.

Visit https://www.peervoice.com/EEZ860 to view the entire programme with slides. After completing “Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?”, participants will be able to: Explain the biological function of the neonatal Fc receptor (FcRn) and its role in regulating immunoglobulin G (IgG) homeostasis; Explain the role of pathogenic IgG in the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and the scientific rationale for FcRn inhibition as a therapeutic strategy; and Evaluate the latest clinical research and ongoing trials assessing FcRn inhibitors in MOGAD and/or CIDP.